Since the fourth quarter, the pharmaceutical sector has rebounded and risen, and 3 Chinese medicine stocks have risen by more than 100%

【Pharmaceutical Network Pharmaceutical Stock Market】 Recently, with the further optimization of epidemic prevention and control measures, the sentiment of "hoarding drugs" has boosted the pharmaceutical sector to rise and limit
in a large area.
On December 7, the pharmaceutical sector set off a tide, as of the close, United Pharmaceutical, Haichen Pharmaceutical, Xuantai Pharmaceutical rose 20% to seal the board, Hengdi Pharmaceutical also rose 19.
98%.

The next day, pharmaceutical stocks remained active
.
Analysts pointed out that since the fourth quarter, the pharmaceutical sector has rebounded and risen, according to statistics, since the fourth quarter, as of December 7, the total market value of the Shenwan biopharmaceutical sector has risen by 17.
32%, and the CSI 300 index has risen by 4.
04%
during the same period.
Among them, traditional Chinese medicine, pharmaceutical commerce, chemical pharmaceuticals and biopharmaceuticals in the secondary industry increased by 34.
37%, 27.
7%, 18.
11% and 16.
18%
respectively.
From the perspective of individual stocks, as of December 7, 4 stocks have risen by more than 100% since the fourth quarter, of which 3 stocks are traditional Chinese medicine stocks in subdivided fields, namely Teyi Pharmaceutical, Yiling Pharmaceutical, and Zhongsheng Pharmaceutical
.
According to the data, the respiratory products of Teyi Pharmaceutical mainly include cough suppressant tablets, Pudi blue anti-inflammatory tablets, cold spirit granules, etc
.
Teyi Pharmaceutical once said in an institutional survey that at present, the company mainly formulates future business strategies
around three categories: respiratory system, skin system and digestive system.
The company will launch two to three varieties of Chinese proprietary medicines every year, and in recent years, it has successively launched Pudi Blue Anti-inflammatory Tablets, Cold Spirit Granules, Skin Disease Blood Poison Pills, Maple Fruit Gastrointestinal Health Tablets, Hypoglycemic Shu Pills, etc
.
The company has cultivated
skin disease blood poison pills and hypoglycemic pills as major varieties after cough tablets.
At present, the company has started the clinical trial of skin disease blood poison pills, and will promote the growth of characteristic Chinese medicine varieties into large varieties of traditional Chinese medicine through clinical research of core varieties and real-world research
.
In addition, Teyi Pharmaceutical said on the interactive platform on December 8 that at present, the company's tablet production capacity is 448,580,000 tablets, and the company will reasonably formulate a production plan
for ibuprofen tablets according to market demand.
At present, ibuprofen tablets are in normal production, and sales have recovered to the same period in 2019 and have increased
.
It is reported that on December 8, Teyi Pharmaceutical rose rapidly intraday, rising more than 2% in 5 minutes, and as of 13:44, it was reported at 29.
82 yuan, with a transaction of 932 million yuan and a turnover rate of 20.
97%.

Yiling Pharmaceutical also rose strongly again on December 8, hitting the limit at 53.
96 yuan during the session, and then appeared a new high; so far, the stock has risen by about 180%
since the low point on September 27.
The data shows that the turnover of Yiling Pharmaceutical has exceeded 10 billion yuan for three consecutive days, with a total market value of 90 billion yuan
.
In terms of news, recently, with the adjustment of epidemic prevention policies and the arrival of influenza season in many places, the market demand for cold drugs such as Lianhua Qingwen has soared
.
Recently, the news of Lianhua Qingwen out of stock has been fermenting, and at the same time, a pharmacy Lianhua Qingwen sold a single box of 100 yuan and rushed to Weibo hot search
.
In this regard, on the evening of December 6, Yiling Pharmaceutical said on the investor interactive platform that the company's supply price of Lianhua Qingwen has remained stable
recently.
If consumers find that individual terminals have price increases, please report
to the relevant local departments in time.
At present, the company is taking various measures to expand production and make every effort to ensure market supply
.
Previously, the company also said when receiving institutional investors that in terms of production, the first phase of the company's Hengshui modern Chinese medicine industrialization project has been put into operation, and the second phase of the project is also advancing
in an orderly manner as planned.
The company's production capacity has been greatly increased, providing a strong guarantee
to meet the incremental market and sudden emergency needs.
In addition, Yiling Pharmaceutical was exposed on December 7 to apply for a patent for Lianhua Qingwen masks, and the instructions said that wearing its products can improve human immunity
.
The main business of Zhongsheng Medicine is drug research and development, production and sales
.
The company's main products are compound thrombosis series products, Zhongsheng pill series products, cefixime dispersible tablets, cefaladine capsules, sucralfate oral suspension
.
Since late September, Zhongsheng Pharmaceutical's stock price has risen sharply, from a low of 11.
88 yuan to 41.
3 yuan, the largest increase of 248% in two months, and the sharp rise in stock prices is related to the antiviral oral drug it is developing, which has entered clinical phase
III.
The relevant person in charge of Zhongsheng Pharmaceutical said that RAY1216 is a powerful and broad-spectrum antiviral 3CL protease inhibitor with independent intellectual property rights, and the company will continue to promote clinical research
with high quality, rapidity and science in accordance with relevant requirements.
The industry said that since the rebound in the fourth quarter, traditional Chinese medicine is also one of
the areas with strong performance.
In addition, from the perspective of equity products led by funds that focus on holding the pharmaceutical sector, among the funds on the market, Hong Kong Stock Connect Pharmaceutical Index related ETFs and Chinese medicine ETFs led the rise, rising by more than 29%
since the fourth quarter.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.